Arca
Skip to content

Chronic spontaneous urticaria

Drug research and approvals for chronic spontaneous urticaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 24 studies of chronic spontaneous urticaria are recruiting on ClinicalTrials.gov, Health Canada has authorized 28 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 24
  • Trials authorized in Canada: 28
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 24 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 28; search them all in Canada trials
Feb 27, 2026A phase 3b long-term efficacy and safety extension study of barzolvolimab in participants with chronic spontaneous urticaria who have completed cdx0159-12 or…BARZOLVOLIMAB (CDX-0159)CELLDEX THERAPEUTICS INCOngoing
Oct 10, 2024A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…BARZOLVOLIMAB (CDX-0159)CELLDEX THERAPEUTICS INCOngoing
Oct 4, 2024A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…CDX-0159CELLDEX THERAPEUTICS INCOngoing
Aug 2, 2024An open-label extension study evaluating the safety, tolerability, pk, immunogenicity, and clinical response of multiple doses of iv ak006 in subjects with h1…AK006ALLAKOS INC.Ongoing
Feb 8, 2024A phase 1, double-blind, randomized, placebo-controlled, sequential, singleand multiple- ascending dose study to evaluate the safety, tolerability, pk, and…AK006ALLAKOS INC.Closed
Aug 18, 2023A global, multicenter, randomized, double-blind, double-dummy, parallel-group, phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib…REMIBRUTINIB (LOU064)Novartis Pharmaceuticals CorporationOngoing
Aug 15, 2023Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effects of ep262 in subjects with chronic spontaneous urticariaEP262ESCIENT PHARMCEUTICALS INCClosed
Mar 13, 2023A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (lou064) for 24 weeks in adolescents…REMIBRUTINIB (LOU064)Novartis Pharmaceuticals CorporationOngoing
Dec 15, 2022A multicenter, open-label phase 3 study: ambulatory blood pressure monitoring in adult patients with chronic spontaneous urticaria inadequately controlled by…REMIBRUTINIB (LOU064)Novartis Pharmaceuticals CorporationClosed
Sep 26, 2022A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to…REMIBRUTINIB (LOU064)Novartis Pharmaceuticals CorporationOngoing

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Apr 23, 2026RhapsidoremibrutinibNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.